| Literature DB >> 26113187 |
Zhu-Ping Xiao1, Wei-Kang Shi2, Peng-Fei Wang3, Wei Wei2, Xiao-Tong Zeng2, Ji-Rong Zhang2, Na Zhu2, Miao Peng2, Bin Peng2, Xiao-Yi Lin2, Hui Ouyang4, Xiao-Chun Peng2, Guang-Cheng Wang2, Hai-Liang Zhu5.
Abstract
Therapies based on urease inhibition are now seriously considered as the first line of treatment for infections caused by Helicobacter pylori. However, the present inhibitors are ineffective or unstable in highly acidic gastric juice. Here, we report a series of benzylanilines as effective inhibitors of H. pylori urease. Out of the obtained twenty-one compounds, N-(3,4-dihydroxybenzyl)-4-nitroaniline (4) was evaluated in detail and shows promising features for development as anti-H. pylori agent. Excellent potency against urease in both cell-free extract and intact cell was observed at low concentrations of 4 (IC50=0.62 ± 0.04 and 1.92 ± 0.09 μM), which showed over 29- and 54-fold increase in potency with respect to the positive control AHA. The SAR analysis revealed that protection of 3,4-dihydroxy group of 4 as methoxy or changes of 4-NO2 will result in a moderate to dramatic decrease in potency.Entities:
Keywords: Benzylaniline; Molecular docking; Peptic ulcer; Urease inhibitor
Mesh:
Substances:
Year: 2015 PMID: 26113187 DOI: 10.1016/j.bmc.2015.06.014
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641